Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Strong topline growth driven by solid performance across key brands.
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Report highlights significant improvements in adolescent well-being in India
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
This tie-up will have no impact on any other brands of the company
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated